This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vinters, H. V. Articles by Pardridge, W. M. Search for Related Content PubMed PubMed Citation Articles by Vinters, H. V. Articles by Pardridge, W. M.

American Journal of Pathology, Vol 137, 233-240, Copyright © 1990 by American Society for Investigative Pathology

REGULAR ARTICLES

Immunoreactive A4 and gamma-trace peptide colocalization in amyloidotic arteriolar lesions in brains of patients with Alzheimer's disease

HV Vinters, GS Nishimura, DL Secor and WM Pardridge
Department of Pathology (Neuropathology), UCLA School of Medicine 90024- 1732.

Cerebral amyloid angiopathy (CAA) defines a biochemically heterogeneous entity that manifests as effacement of cerebral microvessel walls by a fibrillar material with characteristic tinctorial properties. In biochemical terms, the amyloid that infiltrates blood vessels in CAA is composed of the A4 or beta peptide of Alzheimer's disease (AD), a molecule related to gamma trace or cystatin C (seen in patients with hereditary cerebral hemorrhage with amyloidosis in Iceland, HCHWA-I), or the PrP characteristic of spongiform encephalopathy and scrapie. Using antibodies to synthetic peptides representing portions of the 4.2- kd Alzheimer A4 peptide and the gamma-trace peptide, we immunostained sections of brain from patients with AD, senile dementia of Alzheimer's type, and CAA with associated leukoencephalopathy. Immunohistochemical studies demonstrated colocalization of the A4 and gamma-trace peptides within arteriolar walls, but only rarely in A4 amyloidotic capillaries or senile plaque cores of amyloid. When gamma-tracelike reactivity was noted in capillary walls, it was sometimes noted within the cytoplasm of pericytes. Immunostaining was always more intense when the anti-A4 antibody was used as the primary antibody. Gamma-trace immunostaining was more prominent on the adventitial component of arteriolar walls, whereas A4 staining was usually seen more diffusely throughout the blood vessel wall, especially in the media. Rarely individual pericytelike cells showed prominent gamma-trace immunoreactivity. These findings suggest that A4 and gamma-tracelike molecules may colocalize within arteriolar walls within the brains of patients with AD, and highlight the fact that CAA identified with AD and HCHWA-I are not as biochemically distinct as was assumed previously. Furthermore these findings suggest that other peptidases or protease inhibitors may be found within amyloidotic microvessel walls and may contribute to senile brain change and CAA-related strokes, including hemorrhage and encephalomalacia.

This article has been cited by other articles:

				Y. Bai, K. Markham, F. Chen, R. Weerasekera, J. Watts, P. Horne, Y. Wakutani, R. Bagshaw, P. M. Mathews, P. E. Fraser, et al. The in Vivo Brain Interactome of the Amyloid Precursor Protein Mol. Cell. Proteomics, January 1, 2008; 7(1): 15 - 34. [Abstract] [Full Text] [PDF]

				L. Liao, D. Cheng, J. Wang, D. M. Duong, T. G. Losik, M. Gearing, H. D. Rees, J. J. Lah, A. I. Levey, and J. Peng Proteomic Characterization of Postmortem Amyloid Plaques Isolated by Laser Capture Microdissection J. Biol. Chem., August 27, 2004; 279(35): 37061 - 37068. [Abstract] [Full Text] [PDF]

				A. NAGAI, J. K. RYU, S. KOBAYASH, and S. U. KIM Cystatin C Induces Neuronal Cell Death in Vivo Ann. N.Y. Acad. Sci., November 1, 2002; 977(1): 315 - 321. [Full Text] [PDF]

				A. Deng, M. C. Irizarry, R. M. Nitsch, J. H. Growdon, and G. W. Rebeck Elevation of Cystatin C in Susceptible Neurons in Alzheimer's Disease Am. J. Pathol., September 1, 2001; 159(3): 1061 - 1068. [Abstract] [Full Text] [PDF]

				H. Maruyama, Y. Izumi, M. Oda, T. Torii, H. Morino, H. Toji, K. Sasaki, H. Terasawa, S. Nakamura, and H. Kawakami Lack of an association between cystatin C gene polymorphisms in Japanese patients with Alzheimer's disease Neurology, July 24, 2001; 57(2): 337 - 339. [Abstract] [Full Text] [PDF]

				G. Roks, M. Cruts, A.J.C. Slooter, B. Dermaut, A. Hofman, C. Van Broeckhoven, and C.M. Van Duijn The cystatin C polymorphism is not associated with early onset Alzheimer's disease Neurology, July 24, 2001; 57(2): 366 - 367. [Full Text] [PDF]

				U. Finckh, H. von der Kammer, J. Velden, T. Michel, B. Andresen, A. Deng, J. Zhang, T. Muller-Thomsen, K. Zuchowski, G. Menzer, et al. Genetic Association of a Cystatin C Gene Polymorphism With Late-Onset Alzheimer Disease Arch Neurol, November 1, 2000; 57(11): 1579 - 1583. [Abstract] [Full Text] [PDF]

				F. C. Crawford, M. J. Freeman, J. A. Schinka, L. I. Abdullah, M. Gold, R. Hartman, K. Krivian, M. D. Morris, D. Richards, R. Duara, et al. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease Neurology, September 26, 2000; 55(6): 763 - 768. [Abstract] [Full Text] [PDF]

				H. E. d. Vries, J. Kuiper, A. G. d. Boer, T. J. C. V. Berkel, and D. D. Breimer The Blood-Brain Barrier in Neuroinflammatory Diseases Pharmacol. Rev., June 1, 1997; 49(2): 143 - 156. [Abstract] [Full Text] [PDF]

				L. Wei, L. C. Walker, E. Levy, and W. I. Rosenblum Cystatin C: Icelandic-Like Mutation in an Animal Model of Cerebrovascular ß-Amyloidosis Stroke, November 1, 1996; 27(11): 2080 - 2085. [Abstract] [Full Text]

				K. Shimode, S. Kobayashi, K. Imaoka, N. Umegae, and A. Nagai Leukoencephalopathy-Related Cerebral Amyloid Angiopathy With Cystatin C Deposition Stroke, August 1, 1996; 27(8): 1417 - 1419. [Abstract] [Full Text]